Castleark Management LLC Has $8.74 Million Stake in Kiniksa Pharmaceuticals International, plc $KNSA

Castleark Management LLC reduced its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 5.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 181,512 shares of the company’s stock after selling 10,680 shares during the quarter. Castleark Management LLC’s holdings in Kiniksa Pharmaceuticals International were worth $8,740,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. EverSource Wealth Advisors LLC raised its stake in Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after acquiring an additional 532 shares during the period. Osaic Holdings Inc. acquired a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter valued at $31,000. KBC Group NV bought a new position in Kiniksa Pharmaceuticals International during the first quarter worth $34,000. Smartleaf Asset Management LLC bought a new position in Kiniksa Pharmaceuticals International during the fourth quarter worth $36,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Kiniksa Pharmaceuticals International in the fourth quarter valued at $41,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on KNSA shares. Zacks Research raised shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, June 17th. Canaccord Genuity Group lifted their target price on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Jefferies Financial Group upped their price target on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. The Goldman Sachs Group increased their price target on shares of Kiniksa Pharmaceuticals International from $60.00 to $75.00 and gave the company a “buy” rating in a report on Thursday. Finally, Citigroup raised their price objective on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $68.00.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, Director Barry D. Quart sold 13,099 shares of the stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $50.10, for a total transaction of $656,259.90. Following the transaction, the director owned 12,546 shares in the company, valued at $628,554.60. This represents a 51.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 483,654 shares of the stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $51.86, for a total transaction of $25,082,296.44. Following the transaction, the chief executive officer owned 431,904 shares in the company, valued at approximately $22,398,541.44. The trade was a 52.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 628,427 shares of company stock valued at $32,833,228. 51.98% of the stock is owned by company insiders.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ KNSA opened at $62.84 on Monday. The stock’s fifty day moving average price is $56.87 and its two-hundred day moving average price is $50.03. Kiniksa Pharmaceuticals International, plc has a one year low of $26.27 and a one year high of $67.53. The firm has a market cap of $4.83 billion, a price-to-earnings ratio of 69.82 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The firm had revenue of $214.27 million for the quarter, compared to analysts’ expectations of $206.11 million. During the same quarter last year, the business earned $0.11 EPS. The company’s quarterly revenue was up 55.5% compared to the same quarter last year. On average, equities analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.25 earnings per share for the current fiscal year.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.